Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by King's College Hospital NHS Trust.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
King's College Hospital NHS Trust
ClinicalTrials.gov Identifier:
NCT00472875
First received: May 10, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted

May 10, 2007
May 10, 2007
May 2007
Not Provided
Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia [ Time Frame: 1 year ]
Same as current
No Changes Posted
Improvement in counter regulatory hormone response to hypoglycaemia [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
 
Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
Not Provided

To see if using medication called sulphonylureas can help improve symptoms which patients rely on to recognise low blood glucose levels ( hypoglycaemia) and also to see if they can reduce the slowing down in brain function which occurs at hypoglycaemia.

Low blood glucose (hypoglycaemia) is the most common and important side effect of insulin treatment for diabetes. Most episodes are “mild” and lead to symptoms that alert the individual to raise their blood sugar level by consuming sugar or starch (carbohydrate). The body also responds to low blood sugars by producing hormones such as adrenaline and cortisol, which help to restore blood sugar levels to normal. As the brain relies on sugar for fuel, it does not function properly if blood sugar levels drop too low, resulting in confusion and in extreme cases reduced conscious levels.

Repeated hypoglycaemia can blunt the protective symptoms and hormonal responses to hypoglycaemia limiting patients’ ability to recognise and correct hypoglycaemia, putting them at high risk of even more hypoglycaemia (Heller and Cryer, 1991).

Sulphonylureas are tablets used to treat type 2 diabetes that work by stimulating the pancreas to make more insulin. They do this by closing pores called KATP channels which are found on the surface of many cells and control the rate of firing of cells. In the pancreas, closing them causes cells to fire and release insulin. However, in other tissues such as in the brain, these channels have a protective function and they open up during times of lack of fuel, such as lack of oxygen or sugar, preventing the cells from firing and putting them into a resting mode which reduces their energy requirement(Dunn-Meynell, Rawson and Levin 1998). However, if the brain cells responsible for generating symptoms are put into this resting mode, they may not produce symptoms, which may contribute to hypoglycaemia unawareness.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Type 1 Diabetes Mellitus
Drug: Glibenclamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
Not Provided
Not Provided

Inclusion Criteria:

  • Age 18-75
  • Type 1 diabetes (WHO definition) of at least 5 years duration
  • History of impaired awareness of hypoglycaemia (capillary glucose readings < 3.5mmol/l without symptoms on > 3 occasions in the past 3 months (those with intact symptoms will be unlikely to show an improvement and would not really benefit from taking any medication intended just to increase symptoms)

Exclusion Criteria:

  • Pregnancy
  • Severe systemic illness
  • Active malignancy
  • Severe complications of diabetes such as severe visual impairment, severe renal impairment, severe symptomatic autonomic neuropathy
  • Untreated ischemic heart disease, recent stroke
  • Lactose intolerance ( the placebo will contain lactose)
  • Very poor diabetes control (HbA1c > 10%) Liver disease ( increase in ALT / AST > 3x ULN)
  • Chronic Kidney Disease stage 4 or 5 ( eGFR < 30ml/min)
  • Severe untreated thyroid or adrenal insufficiency ( must be treated and on stable doses for at least 6 weeks)
Both
18 Years to 75 Years
No
Contact: Pratik Choudhary, MBBS, MRCP +44 203 299 9000 ext 2311 pratik.choudhary@kcl.ac.uk
Contact: Stephanie A Amiel, MD, FRCP +44 203 299 9000 ext 4164 stephanie.amiel@kcl.ac.uk
United Kingdom
 
NCT00472875
07/Q0703/18, JDRF grant number 5-2007-478
No
Not Provided
King's College Hospital NHS Trust
Not Provided
Principal Investigator: Pratik Choudhary, MBBS MRCP King's College London
King's College Hospital NHS Trust
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP